Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

[Influence of oxaliplatin combined with LCP on proliferation and apoptosis of colon cancer cell line HT29].

Lu WQ, Wang F, Liu HY.

Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Jan;16(1):84-8. Chinese.

PMID:
23355248
2.

[Role of BH3-only gene in the oxaliplatin-induced apoptosis of colon cancer cells].

Tu SL, Yuan H, He XJ, Ma YY.

Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Jun;16(6):538-42. Chinese.

PMID:
23801206
3.

Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells.

Hua H, Chen W, Shen L, Sheng Q, Teng L.

Acta Biochim Biophys Sin (Shanghai). 2013 Sep;45(9):773-9. doi: 10.1093/abbs/gmt071. Epub 2013 Jun 19.

PMID:
23786838
4.

Down-regulation of p110β expression increases chemosensitivity of colon cancer cell lines to oxaliplatin.

Liu W, Wang G, Cao X, Luo X, Li Z, Deng Y, Li X, Wang S, Liu M, Hu J, Wang J.

J Huazhong Univ Sci Technolog Med Sci. 2012 Apr;32(2):280-6. doi: 10.1007/s11596-012-0049-z. Epub 2012 Apr 20.

PMID:
22528234
5.

Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.

Serova M, Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen AK, Laar ES, Waters SJ, Cvitkovic E, Raymond E.

Cancer Chemother Pharmacol. 2006 Apr;57(4):491-9. Epub 2005 Aug 2.

PMID:
16075278
6.

The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines.

Xu JM, Azzariti A, Colucci G, Paradiso A.

Cancer Chemother Pharmacol. 2003 Dec;52(6):442-8. Epub 2003 Sep 16.

PMID:
13680161
7.

Gene and protein expression in the oxaliplatin-resistant HT29/L-OHP human colon cancer cell line.

Xiang Z, Kang QJ, Xiang X.

Genet Mol Res. 2015 Sep 21;14(3):11013-22. doi: 10.4238/2015.September.21.14.

8.

Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines.

Atallah D, Marsaud V, Radanyi C, Kornprobst M, Rouzier R, Elias D, Renoir JM.

Int J Hyperthermia. 2004 Jun;20(4):405-19.

PMID:
15204521
9.

Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.

El Fajoui Z, Toscano F, Jacquemin G, Abello J, Scoazec JY, Micheau O, Saurin JC.

Gastroenterology. 2011 Aug;141(2):663-73. doi: 10.1053/j.gastro.2011.04.055. Epub 2011 Apr 30.

PMID:
21683075
10.

Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin.

Zhao S, Cai J, Bian H, Gui L, Zhao F.

Cancer Invest. 2009 Jul;27(6):636-40. doi: 10.1080/07357900802672738.

PMID:
19387877
11.

Combination treatment with oxaliplatin and mangiferin causes increased apoptosis and downregulation of NFκB in cancer cell lines.

du Plessis-Stoman D, du Preez J, van de Venter M.

Afr J Tradit Complement Altern Med. 2011;8(2):177-84. Epub 2010 Dec 30.

12.

Triptolide synergistically enhances antitumor activity of oxaliplatin in colon carcinoma in vitro and in vivo.

Liu Y, Xiao E, Yuan L, Li G.

DNA Cell Biol. 2014 Jul;33(7):418-25. doi: 10.1089/dna.2014.2356. Epub 2014 Apr 10.

PMID:
24720675
13.

Thermotherapy enhances oxaliplatin-induced cytotoxicity in human colon carcinoma cells.

Zhang XL, Hu AB, Cui SZ, Wei HB.

World J Gastroenterol. 2012 Feb 21;18(7):646-53. doi: 10.3748/wjg.v18.i7.646.

14.

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.

Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE.

Cancer Res. 2009 May 1;69(9):3842-9. doi: 10.1158/0008-5472.CAN-08-2246. Epub 2009 Apr 21.

15.
16.

Oxaliplatin down-regulates survivin by p38 MAP kinase and proteasome in human colon cancer cells.

Liu HF, Hu HC, Chao JI.

Chem Biol Interact. 2010 Dec 5;188(3):535-45. doi: 10.1016/j.cbi.2010.08.001. Epub 2010 Aug 12.

PMID:
20708607
17.

The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin.

Almendro V, Ametller E, García-Recio S, Collazo O, Casas I, Augé JM, Maurel J, Gascón P.

PLoS One. 2009;4(3):e4728. doi: 10.1371/journal.pone.0004728. Epub 2009 Mar 6.

18.

MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.

Tentori L, Muzi A, Dorio AS, Dolci S, Campolo F, Vernole P, Lacal PM, Praz F, Graziani G.

Cancer Chemother Pharmacol. 2013 Jul;72(1):117-25. doi: 10.1007/s00280-013-2175-0. Epub 2013 May 1.

PMID:
23636450
19.

Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.

Raymond E, Louvet C, Tournigand C, Coudray AM, Faivre S, De Gramont A, Gespach C.

Int J Oncol. 2002 Aug;21(2):361-7.

PMID:
12118332
20.

PCK3145 inhibits proliferation and induces apoptosis in breast and colon cancer cells.

Kostopoulos A, Papageorgiou E, Koutsilieris M, Sivolapenko G.

Anticancer Res. 2015 Mar;35(3):1377-84.

PMID:
25750288

Supplemental Content

Support Center